Applying Comparative of Anticoagulant and Thrombolytic Sak-Hirudin Fusion Protein Used in Cardiopulmonary Bypass
10.3969/j.issn.1671-7414.2015.02.006
- VernacularTitle:重组葡激酶-水蛭素融合蛋白在体外循环抗凝溶栓中的应用比较
- Author:
Chunhua LI
;
Nian ZHAO
;
Wu CHEN
- Publication Type:Journal Article
- Keywords:
sak-hirudin fusion protein;
cardiopulmonary bypass;
cytocompatibility;
hemolysis
- From:
Journal of Modern Laboratory Medicine
2015;(2):19-22,26
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the applying comparative values of anticoagulant and thrombolytic Sak-hirudin fusion protein used in cardiopulmonary bypass.Methods From february 2013 to July 2014,selected nitinol sheet into uncoated group (group A),base coated group (chitosan,group B),chitosan/ Sak group (group C),chitosan/hirudin group (group D),chitosan/Sak-hirudin fusion protein group (group E),there were included in the fresh round of blood hemolysis,the blood cell hemolysis rates were calculated.Meanwhile used the healthy newborns umbilical vein endothelial cells were added into various categories nitinol sheet for cell compatibility testing.Results The samples hemolysis rates in the 5 groups were around 1.5% and the RBC,WBC and PLT counts compared in the 5 groups were showed no differences (P <0.05).The ex-tent of proliferation and adhesion in the group E were significantly lower than the other four groups,compared to significant differences (P <0.05).There were no differences to compare group A and group B (P >0.05).Randomized double-blind cell count result shows that the group C,D and E compared to the group A,B were more significant differences (P <0.05), at the same time,the group E compared to the group C,D differences were statistically significant (P <0.05).Conclusion Compared to Staphylokinase and hirudin alone,Sak-hirudin fusion protein used in cardiopulmonary bypass can play stronger anticoagulant and antithrombotic effects,its safety and ensures the effectiveness that interventional treatment of cardiovascu-lar disease.
